• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上呼吸道对 SARS-CoV-2 炎症反应的纵向分析显示,与症状无关,与病毒载量有关。

Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms.

机构信息

Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.

Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.

出版信息

J Clin Immunol. 2021 Nov;41(8):1723-1732. doi: 10.1007/s10875-021-01134-z. Epub 2021 Sep 28.

DOI:10.1007/s10875-021-01134-z
PMID:34581925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8476983/
Abstract

BACKGROUND

SARS-CoV-2 infection leads to high viral loads in the upper respiratory tract that may be determinant in virus dissemination. The extent of intranasal antiviral response in relation to symptoms is unknown. Understanding how local innate responses control virus is key in the development of therapeutic approaches.

METHODS

SARS-CoV-2-infected patients were enrolled in an observational study conducted at the Geneva University Hospitals, Switzerland, investigating virological and immunological characteristics. Nasal wash and serum specimens from a subset of patients were collected to measure viral load, IgA specific for the S1 domain of the spike protein, and a cytokine panel at different time points after infection; cytokine levels were analyzed in relation to symptoms.

RESULTS

Samples from 13 SARS-CoV-2-infected patients and six controls were analyzed. We found an increase in CXCL10 and IL-6, whose levels remained elevated for up to 3 weeks after symptom onset. SARS-CoV-2 infection also induced CCL2 and GM-CSF, suggesting local recruitment and activation of myeloid cells. Local cytokine levels correlated with viral load but not with serum cytokine levels, nor with specific symptoms, including anosmia. Some patients had S1-specific IgA in the nasal cavity while almost none had IgG.

CONCLUSION

The nasal epithelium is an active site of cytokine response against SARS-CoV-2 that can last more than 2 weeks; in this mild COVID-19 cohort, anosmia was not associated with increases in any locally produced cytokines.

摘要

背景

SARS-CoV-2 感染会在上呼吸道产生高病毒载量,这可能是病毒传播的决定因素。目前尚不清楚与症状相关的鼻内抗病毒反应的程度。了解局部先天反应如何控制病毒是开发治疗方法的关键。

方法

在瑞士日内瓦大学医院进行的一项观察性研究中招募了 SARS-CoV-2 感染患者,该研究调查了病毒学和免疫学特征。在感染后不同时间点,从一部分患者中采集鼻洗液和血清标本,以测量病毒载量、针对刺突蛋白 S1 结构域的 IgA 特异性和细胞因子谱;分析细胞因子水平与症状的关系。

结果

分析了 13 名 SARS-CoV-2 感染患者和 6 名对照者的样本。我们发现 CXCL10 和 IL-6 增加,其水平在症状出现后长达 3 周仍保持升高。SARS-CoV-2 感染还诱导了 CCL2 和 GM-CSF,提示局部招募和激活髓样细胞。局部细胞因子水平与病毒载量相关,但与血清细胞因子水平或特定症状(包括嗅觉丧失)无关。一些患者的鼻腔中存在 S1 特异性 IgA,而几乎没有 IgG。

结论

鼻上皮是针对 SARS-CoV-2 的细胞因子反应的活跃部位,这种反应可持续超过 2 周;在这个轻度 COVID-19 队列中,嗅觉丧失与任何局部产生的细胞因子增加无关。

相似文献

1
Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms.上呼吸道对 SARS-CoV-2 炎症反应的纵向分析显示,与症状无关,与病毒载量有关。
J Clin Immunol. 2021 Nov;41(8):1723-1732. doi: 10.1007/s10875-021-01134-z. Epub 2021 Sep 28.
2
Human Nasal and Lung Tissues Infected with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract.人鼻腔和肺部组织感染 SARS-CoV-2 提供了在上呼吸道和下呼吸道中不同组织特异性和病毒特异性先天免疫反应的见解。
J Virol. 2021 Jun 24;95(14):e0013021. doi: 10.1128/JVI.00130-21.
3
SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms.SARS-CoV-2 黏膜抗体的产生和持久性及其与病毒载量和 COVID-19 症状的关系。
Nat Commun. 2021 Sep 23;12(1):5621. doi: 10.1038/s41467-021-25949-x.
4
Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.无症状、轻度和重症有症状 SARS-CoV-2 感染患者的病毒载量、淋巴细胞亚群和细胞因子:一项回顾性研究。
Virol J. 2021 Jun 12;18(1):126. doi: 10.1186/s12985-021-01597-x.
5
Circulating Type I Interferon Levels in the Early Phase of COVID-19 Are Associated With the Development of Respiratory Failure.循环 I 型干扰素水平在 COVID-19 早期与呼吸衰竭的发展有关。
Front Immunol. 2022 Feb 14;13:844304. doi: 10.3389/fimmu.2022.844304. eCollection 2022.
6
Seawater nasal wash to reduce symptom duration and viral load in COVID-19 and upper respiratory tract infections: a randomized controlled multicenter trial.海水鼻腔冲洗在 COVID-19 和上呼吸道感染中减少症状持续时间和病毒载量的随机对照多中心试验。
Eur Arch Otorhinolaryngol. 2024 Jul;281(7):3625-3637. doi: 10.1007/s00405-024-08518-y. Epub 2024 Feb 20.
7
The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.新型冠状病毒(SARS-CoV-2)疫苗的黏膜和血清免疫应答。
Front Immunol. 2021 Oct 12;12:744887. doi: 10.3389/fimmu.2021.744887. eCollection 2021.
8
Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.尽管 COVID-19 患者存在强烈的外周炎症,但黏膜抗病毒反应延迟。
J Infect Dis. 2024 Jul 25;230(1):e17-e29. doi: 10.1093/infdis/jiad590.
9
Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.新冠肺炎患者血清中数月来持续存在对 SARS-CoV-2 的中和活性。
Viruses. 2020 Nov 27;12(12):1357. doi: 10.3390/v12121357.
10
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.早期针对 SARS-CoV-2 的鼻腔 I 型 IFN 免疫被针对 I 型 IFN 的自身抗体患者削弱。
J Exp Med. 2021 Oct 4;218(10). doi: 10.1084/jem.20211211. Epub 2021 Aug 6.

引用本文的文献

1
Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC).揭示新冠后综合征(PASC)中的差异与联系:急性新冠肺炎与新冠病毒2型(SARS-CoV-2)急性后遗症中的病毒载量和细胞因子特征
Biomedicines. 2024 Aug 23;12(9):1941. doi: 10.3390/biomedicines12091941.
2
Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study.体外光化学疗法作为对标准治疗无反应的重症和危重症成人COVID-19的一种可能治疗方法:一项初步研究。
J Clin Med. 2023 Jul 29;12(15):5000. doi: 10.3390/jcm12155000.
3

本文引用的文献

1
Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.更正:在患有抗I型干扰素自身抗体的患者中,针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的早期鼻腔I型干扰素免疫功能受损。
J Exp Med. 2021 Oct 4;218(10). doi: 10.1084/jem.2021121108132021c. Epub 2021 Aug 20.
2
In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection.在鼻腔黏膜分泌物中,严重和轻度 SARS-CoV-2 感染中存在不同的 IFN 和 IgA 反应。
Front Immunol. 2021 Feb 25;12:595343. doi: 10.3389/fimmu.2021.595343. eCollection 2021.
3
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.
Influence of SARS-CoV-2 Status and Aging on the Nasal and Fecal Immunological Profiles of Elderly Individuals Living in Nursing Homes.
SARS-CoV-2 状态和衰老对居住在养老院的老年个体的鼻腔和粪便免疫谱的影响。
Viruses. 2023 Jun 20;15(6):1404. doi: 10.3390/v15061404.
4
Proteomic Analysis of Mucosal and Systemic Responses to SARS-CoV-2 Antigen.SARS-CoV-2抗原黏膜和全身反应的蛋白质组学分析
Vaccines (Basel). 2023 Feb 2;11(2):334. doi: 10.3390/vaccines11020334.
5
Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study.一项密集采样纵向监测研究中未接种疫苗参与者的早期新冠病毒动态及免疫反应
Commun Med (Lond). 2022 Oct 11;2:129. doi: 10.1038/s43856-022-00195-4. eCollection 2022.
6
Role of the humoral immune response during COVID-19: guilty or not guilty?体液免疫反应在 COVID-19 中的作用:有罪还是无罪?
Mucosal Immunol. 2022 Jun;15(6):1170-1180. doi: 10.1038/s41385-022-00569-w. Epub 2022 Oct 4.
7
Respiratory and systemic monocytes, dendritic cells, and myeloid-derived suppressor cells in COVID-19: Implications for disease severity.COVID-19 中的呼吸和全身单核细胞、树突状细胞和髓系来源的抑制性细胞:对疾病严重程度的影响。
J Intern Med. 2023 Feb;293(2):130-143. doi: 10.1111/joim.13559. Epub 2022 Aug 31.
8
Tissue immunity to SARS-CoV-2: Role in protection and immunopathology.组织对 SARS-CoV-2 的免疫:在保护和免疫病理中的作用。
Immunol Rev. 2022 Aug;309(1):25-39. doi: 10.1111/imr.13112. Epub 2022 Jun 25.
SARS-CoV-2、SARS-CoV 和 MERS-CoV 的病毒载量动态、病毒脱落持续时间和传染性:系统评价和荟萃分析。
Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.
4
Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19.COVID-19 患者中嗅黏膜 SARS-CoV-2 入侵作为中枢神经系统进入的途径。
Nat Neurosci. 2021 Feb;24(2):168-175. doi: 10.1038/s41593-020-00758-5. Epub 2020 Nov 30.
5
The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection.鼻腔微环境在 SARS-CoV-2 感染的传播、调节和临床进展中的核心作用。
Mucosal Immunol. 2021 Mar;14(2):305-316. doi: 10.1038/s41385-020-00359-2. Epub 2020 Nov 26.
6
Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020.2020 年 5 月至 6 月,德国成功控制的早期热点地区成年人中基于血清学和 PCR 的 SARS-CoV-2 感染累积发病率(CoMoLo 研究)。
Euro Surveill. 2020 Nov;25(47). doi: 10.2807/1560-7917.ES.2020.25.47.2001752.
7
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.新冠病毒感染轻症与重症患者的系统性及黏膜性抗体对 SARS-CoV-2 的应答特征。
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. doi: 10.1016/j.jaci.2020.10.040. Epub 2020 Nov 20.
8
Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19.白细胞向肺部及其他部位的迁移:COVID-19 从流感中得到的教训。
Nat Rev Immunol. 2021 Jan;21(1):49-64. doi: 10.1038/s41577-020-00470-2. Epub 2020 Nov 19.
9
Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses.上呼吸道基因表达显示,与其他呼吸道病毒相比,SARS-CoV-2 抑制了免疫反应。
Nat Commun. 2020 Nov 17;11(1):5854. doi: 10.1038/s41467-020-19587-y.
10
Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.《COVID-19 中的每日病毒动力学和固有及适应性免疫反应评估:病例系列》。
mSphere. 2020 Nov 11;5(6):e00827-20. doi: 10.1128/mSphere.00827-20.